Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy

[1]  Familial partial lipodystrophy , 2020, Definitions.

[2]  F. Santini,et al.  Diagnosis and treatment of lipodystrophy: a step-by-step approach , 2018, Journal of Endocrinological Investigation.

[3]  P. Gorden,et al.  Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy , 2018, Endocrine.

[4]  E. Chiquette,et al.  Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges , 2017, Diabetes, metabolic syndrome and obesity : targets and therapy.

[5]  Ş. Savaş-Erdeve,et al.  Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy. , 2017, Metabolism: clinical and experimental.

[6]  R. Muniyappa,et al.  Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy. , 2017, Journal of clinical lipidology.

[7]  D. Dunger,et al.  The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline , 2016, The Journal of clinical endocrinology and metabolism.

[8]  F. Casanueva,et al.  Type 1 familial partial lipodystrophy: understanding the Köbberling syndrome , 2016, Endocrine.

[9]  F. Travert,et al.  One‐year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes , 2016, Diabetes, obesity & metabolism.

[10]  E. Oral,et al.  Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program , 2016, Journal of diabetes & metabolism.

[11]  P. Gorden,et al.  Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy , 2016, Expert review of clinical pharmacology.

[12]  A. Gastaldelli,et al.  The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis , 2015, Nutrients.

[13]  N. Patni,et al.  Congenital generalized lipodystrophies—new insights into metabolic dysfunction , 2015, Nature Reviews Endocrinology.

[14]  T. Atik,et al.  Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities. , 2015, Metabolism: clinical and experimental.

[15]  P. Gorden,et al.  Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. , 2015, The Journal of clinical endocrinology and metabolism.

[16]  K. Rother,et al.  Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. , 2014, The Journal of clinical endocrinology and metabolism.

[17]  R. Shamburek,et al.  Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides. , 2014, The Journal of clinical endocrinology and metabolism.

[18]  J. Chan,et al.  The clinical approach to the detection of lipodystrophy - an AACE consensus statement. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[19]  P. Gorden,et al.  Consequences of Stopping and Restarting Leptin in an Adolescent with Lipodystrophy , 2012, Hormone Research in Paediatrics.

[20]  C. Quittner,et al.  Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. , 2012, The Journal of clinical endocrinology and metabolism.

[21]  J. Chan,et al.  Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[22]  A. Garg.  Lipodystrophies: Genetic and Acquired Body Fat Disorders , 2011 .

[23]  A. Garg.  Acquired and inherited lipodystrophies. , 2004, The New England journal of medicine.

[24]  E. Oral.  Lipoatrophic Diabetes and Other Related Syndromes , 2003, Reviews in Endocrine and Metabolic Disorders.

[25]  M. Reitman,et al.  Leptin-replacement therapy for lipodystrophy. , 2002, The New England journal of medicine.

[26]  A. Garg.  Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). , 2000 .

[27]  P. Cronin.  A step-by-step approach , 2011 .

[28]  A. Garg.  Lipodystrophies: Genetic and Acquired Body Fat Disorders , 2011 .

[29]  P. Gorden,et al.  Efficacy of leptin therapy in the different forms of human lipodystrophy , 2009, Diabetologia.